

# SPOG in Publications in 2023

Below is a list of the publications that appeared in peer-reviewed scientific journals in 2023 in which staff members of SPOG member hospitals were actively involved. Publications by people from the wider SPOG network are no longer listed.

Green: publications with a green background relate directly to studies in which SPOG was involved.

Blue: publications to which Young Investigator Award winners have contributed are highlighted in blue.

## Publications cited in PubMed or in peer reviewed journals

- 1 Akkari FG, Stathopoulos C, Puccinelli F, Hajdu SD, **Beck Popovic M**, Munier FL, Saliou G, Bartolini B. Absorbable gelatin compressed sponge (Gelfoam) embolization of distal external carotid artery branches in intra-arterial chemotherapy for retinoblastoma. *J Neurointerv Surg*. (Epub 2023); jnis-2023-020206. doi:10.1136/jnis-2023-020206.
- 2 Altherr A, Bolliger C, Kaufmann M, Dyntar D, **Scheinemann K**, Michel G, Mader L, Roser K. Education, Employment, and Financial Outcomes in Adolescent and Young Adult Cancer Survivors – A Systematic Review. *Curr Oncol*. (2023); 30(10), 8720-8762. doi:10.3390/currconcol30100631.
- 3 Andersson NG, Labarque V, **Kartal-Kaess M**, Pinto F, Mikkelsen TS, Ljung R, Group PS. Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children. *Haematologica*. (Epub 2023). doi:10.3324/haematol.2023.284095.
- 4 André P, Chtioui H, Dao K, Rothuizen LE, Di Paolo ER, **Diezi M**, Crisinel PA, Cachat F, Chehade H, Buclin T. Estimating glomerular filtration rate from serum creatinine concentration in children with augmented renal clearance: all formulas are equivocal, but some are more equivocal than others. *Kidney Int*. (2023); 103(1), 225–226. doi:10.1016/j.kint.2022.10.015.
- 5 Bader P, Pötschger U, Dalle JH, Moser LM, Balduzzi A, **Ansari M**, Buechner J, **Güngör T**, Iversen M, Krivan G, Pichler H, Renard M, Staciuk R, Sedlacek P, Stein J, Heusel JR, Truong T, Wachowiak J, Yesilipek A, Locatelli F, Peters C. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. *Blood Adv*. (2024); 8(2), 416–428. doi:10.1182/bloodadvances.2023010591.
- 6 Baruchel A, **Bourquin JP**, Crispino J, Cuartero S, Hasle H, Hitzler J, Klusmann JH, Izraeli S, Lane AA, Malinge S, Rabin KR, Roberts I, Ryeom S, Tasian SK, Wagenblast E. Down syndrome and leukemia: from basic mechanisms to clinical advances. *Haematologica*. (2023); 108(10), 2570-2581. doi:10.3324/haematol.2023.283225.
- 7 Beckhaus J, Boekhoff S, **Scheinemann K**, **Schilling FH**, Fleischhack G, Binder G, Bison B, Pietsch T, Friedrich C, Müller HL. Perinatally diagnosed congenital craniopharyngiomas in the KRANIOPHARYNGEOM trials. *Endocr Connect*. (2023); 12(12), e230294. doi:10.1530/EC-23-0294.
- 8 Belle FN, **Schindera C**, **Ansari M**, Armstrong GT, **Beck Popovic M**, Howell R, Leisenring WM, Meacham LR, Roessler J, Spycher BD, Tonorezos E, **von der Weid NX**, Yasui Y, Oeffinger KC, Kuehni CE. Risk factors for overweight and obesity after childhood acute lymphoblastic leukemia in North America and Switzerland: A comparison of two cohort studies. *Cancer Med*. (2023); 12(20), 20423–20436. doi:10.1002/cam4.6588.
- 9 Ben Hassine K, **Cepi F**, **Baleydiere F**, **von Bueren AO**, **Beck Popovic M**, **Ansari M**. Médecine de précision dans le traitement des cancers pédiatriques [Precision medicine in the treatment of pediatric cancers]. *Rev Med Suisse*. (2023); 19(815), 380–387. French. doi:10.53738/REVMED.2023.19.815.380.
- 10 Ben Hassine K, Seydoux C, Khier S, Daali Y, Medinger M, Halter J, Heim D, Chalandon Y, Schanz U, Nair G, Cantoni N, Passweg JR, Uppugunduri CRS, **Ansari M**. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT. *Transplant Cell Ther*. (2023); S2666-6367(23), 01715-3. doi:10.1016/j.jct.2023.12.003. Epub ahead of print.
- 11 Bielack SS, Blattmann C, Hassenpflug W, Kager L, **Kühne T**, Kevric M, Schlegel PG, Mettmann V, Sorg B, Hecker-Nolting S. Osteosarcoma Arising After Ewing Sarcoma or Vice Versa: A Report of 20 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS). *Anticancer Res*. (2023); 43(11), 4975–4981. doi:10.21873/anticancer.16696.
- 12 Bielack SS, Kager L, **Kühne T**, Langer T, Reichardt P, Blattmann C, Kevric M, Mettmann V, Sorg B, Hecker-Nolting S. Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS). *Cancers (Basel)*. (2023); 15(5), 1520. doi:10.3390/cancers15051520.
- 13 Bielack SS, Lindner LH, Egerer G, Benzler K, Blattmann C, Grube M, Hahn D, Kager L, **Kühne T**, Mettmann V, Reichardt P, Hecker-Nolting S. Osteosarcomas in older adults: A report from the Cooperative Osteosarcoma Study Group. *J Geriatr Oncol*. (2023); 14(3), 101445. doi:10.1016/j.jgo.2023.101445.
- 14 **Bodmer N**, Hecker-Nolting S, Friedel G, Blattmann C, Kager L, Kessler T, Kevric M, **Kühne T**, Mettmann V, Müller-Abt P, Sorg B, Theobald M, Bielack SS. Primary osteosarcoma of the ribs: A report from the Cooperative Osteosarcoma Study Group. *Cancer*. (2023); 129(12), 1895-1903. doi:10.1002/cncr.34744. Epub 2023 Mar 17.
- 15 Borgatta M, Wild P, Delobel J, **Renella R**, Hopf NB. Hematological variations in healthy participants exposed 2 h to propylene glycol ethers under controlled conditions. *Sci Total Environ*. (2023); 879:162865. doi:10.1016/j.scitotenv.2023.162865.

Publications cited in PubMed or in peer reviewed journals

- 16 Bratteteig M, Rueegg CS, Raastad T, Grydeland M, Torsvik IK, **Schindera C**, Ruud E, Anderssen SA. Physical Activity, Fitness, and Cardiovascular Disease Risk in Adolescent Childhood Cancer Survivors Compared to Controls: The Physical Activity in Childhood Cancer Survivors Study. *J Adolesc Young Adult Oncol*. (Epub 2023). doi:10.1089/jayao.2023.0063.
- 17 Brivio E, Pennesi E, Willems ME, Huitema AD, Jiang Y, van Tinteren HDR, van der Velden VHJ, Beverloo BH, den Boer ML, Rammeloo LAJ, Hudson C, Heerema N, Kowalski K, Zhao H, Kuttschreuter L, Bautista Sirvent FJ, Bukowinski A, Rizzari C, Pollard J, Murillo-Sanjuán L, Kutny M, Zarnegar-Lumley S, Redell M, Cooper S, Bertrand Y, Petit A, Krystal J, Metzler M, Lancaster D, **Bourquin JP**, Motwani J, van der Sluis IM, Locatelli F, Roth ME, Hijji N, Zwaan CM. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. *J Clin Oncol*. (Epub 2023); JCO2300897. doi:10.1200/JCO.23.00897.
- 18 Brock P, Meijer A, Kogner P, **Ansari M**, Capra M, Geller J, Heuvel-Eibrink MVD, Knight K, Kruger M, Lindemulder S, Maibach R, O'Neill A, Papadakis V, Rajput K, Bleyer A, Bouffet E, Sullivan M. Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it. *Pediatr Blood Cancer*. (2023); 70(5), e30248. doi:10.1002/pbc.30248.
- 19 Bronz G, Gianini J, Passi AG, **Rizzi M**, Bergmann MM, Milani GP, Lava SAG, Bianchetti MG, Terziroli Beretta-Piccoli B, Vanoni F. Autoimmune markers and vascular immune deposits in Finkelstein-Seidlmayer vasculitis: Systematic literature review. *J Autoimmun*. (2023); 136, 103002. doi:10.1016/j.jaut.2023.103002.
- 20 Buhler S, Sollet ZC, Bettens F, Schäfer A, **Ansari M**, Ferrari-Lacraz S, Villard J. HLA variants and TCR diversity against SARS-CoV-2 in the pre-COVID-19 era. *HLA*. (2023); 102(6), 720–730. doi:10.1111/tan.15158.
- 21 Capogiri M, De Micheli AJ, Lassaletta A, Muñoz DP, Coppé JP, Mueller S, **Guerreiro Stucklin AS**. Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead? *Front Oncol*. (2023); 12:1074726. doi:10.3389/fonc.2022.1074726.
- 22 Cetin M, **Gumy-Pause F**, Gualtieri R, Posfay-Barbe KM, Blanchard-Rohner G. Vaccine Immunity in Children After Hematologic Cancer Treatment: A Retrospective Single-center Study. *J Pediatr Hematol Oncol*. (Epub 2023); 46(1):e51–e59. doi:10.1097/MPH.0000000000002774.
- 23 Cho SJ, Ranganathan S, Alaggio R, Maibach R, Tanaka Y, Inoue T, Leuschner I, de Krijger R, Vokuhl C, Krailo M, Malogolowkin M, Meyers R, Czaderna P, Hiyama E, **Ansari M**, Morland B, Trobaugh-Lotrario A, O'Neill AF, Rangaswami A, Häberle B, López-Terrada D. Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC). *Pediatr Blood Cancer*. (Epub 2023); e30505. doi:10.1002/pbc.30505.
- 24 Chouraqui JP, **Renella R**, Turck D. Assessment of dietary iron intake and sources in early childhood in a nationally representative cross-sectional survey. *J Acad Nutr Diet*. (Epub 2023), S2212-2672(23)01764-1. doi:10.1016/j.jand.2023.12.009.
- 25 Christen S, Roser K, Harju E, **Gumy Pause F**, Mader L, Vetsch J, **von Bueren AO**, Michel G. Worries and anxiety in parents of adult survivors of childhood cancer: A report from the Swiss Childhood Cancer Survivor Study-Parents. *Pediatr Blood Cancer*. (2023); 70(5), e30246. doi:10.1002/pbc.30246.
- 26 D'Hooghe E, **Furtwängler R**, Chowdhury T, Vokuhl C, Al-Saadi R, Pritchard-Jones K, Graf N, Vujanic GM. Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies (2001–2020). *Cancer*. (2023); 129(12), 1930–1938. doi:10.1002/cncr.34734.
- 27 Dorenkamp M, Porret N, **Diepold M**, Rovó A. A De Novo Frameshift Mutation in RPL5 with Classical Phenotype Abnormalities and Worsening Anemia Diagnosed in a Young Adult-A Case Report and Review of the Literature. *Medicina (Kaunas)*. (2023); 59(11), 1953. doi:10.3390/medicina59111953.
- 28 El Masri AER, Tobler C, **Breunis WB**, **von Bueren AO**, **Ansari M**, Samer CF. Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023? *Front Pharmacol*. (2023); 1130548. doi:10.3389/fphar.2023.1130548.
- 29 **Farrag A**, Mohammed K, Ghazaly MH, Berthold F. Noncompliance of pediatric cancer patients with chemotherapy: A single-center experience in a lower-middle income country. *Pediatr Hematol Oncol*. (Epub 2023), 1–13. doi:10.1080/08880018.2023.2256780.
- 30 Fialkowski E, Sudour-Bonnange H, Vujanic GM, Shamberger RC, Chowdhury T, Aldrink JH, Davick J, Sandberg J, **Furtwängler R**, Mullen E. The varied spectrum of nephroblastomatosis, nephrogenic rests, and Wilms tumors: Review of current definitions and challenges of the field. *Pediatr Blood Cancer*. (2023); 70 Suppl 2:e30162. doi:10.1002/pbc.30162.
- 31 Fischer K, Carcao M, Male C, Ranta S, Pergantou H, Kenet G, **Kartal-Kaess M**, Königs C, Carvalho M, Alvarez MT, Brakenhoff T, Chambost H, van den Berg HM. Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort. *J Thromb Haemost*. (2023); 21(3), 700–703. doi:10.1016/j.jtha.2022.11.020.
- 32 Franke FC, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi TW, Wohlgemuth WA, Mauz-Körholz C, Körholz D, Kluge R, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekavka T, Attarbaschi A, **Ceppi F**, Hrkavova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Moellers M, Buerke B, Stoevesandt D. Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma. *Pediatr Blood Cancer*. (2023); 70(8), e30421. doi:10.1002/pbc.30421.
- 33 Fuchs J, Schunn MC, Schäfer JF, Ebinger M, Graf N, **Furtwängler R**, Warmann SW. Redo nephron-sparing surgery in stage V pediatric renal tumors - A report from the SIOP/GPOH study group for renal tumors. *Eur J Surg Oncol*. (Epub 2023); 50(1), 107265. doi:10.1016/j.ejso.2023.107265.
- 34 Gavillet M, Rufer N, Grandoni F, **Rizzi M**, Vulliamoz N, Baud D, Alberio L, Canellini G, Legardeur H. Successful outcome of pregnancy post-allogeneic stem cell transplant despite severe RH1 alloimmunization: A case report. *Br J Haematol*. (2023); 201(3), 581–584. doi:10.1111/bjh.18741.

Publications cited in PubMed or in peer reviewed journals

- 35 González-López TJ, **Schifferli A**. Early immunomodulation in immune thrombocytopenia – A report of the ICIS meeting in Lenzerheide, Switzerland 2022. *Br J Haematol.* (2023); 203(1), 101–111. doi:10.1111/bjh.19082.
- 36 Grand-Guillaume J, Mansi R, Gaonkar RH, Zanger S, Fani M, Eugster PJ, **Beck Popovic M**, Grouzmann E, Abid K. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors. *J Transl Med.* (2023); 21(1), 604. doi:10.1186/s12967-023-04466-z.
- 37 Hardin EC, Schmid S, Sommerkamp A, Bodden C, Heipertz AE, Sievers P, Wittmann A, Milde T, Pfister SM, von Deimling A, Horn S, Herz NA, Simon M, Perera AA, Azizi A, Cruz O, Curry S, Van Damme A, Garami M, Hargrave D, Kattamis A, Kotnik BF, Lähteenmäki P, **Scheinemann K**, Schouten-van Meeteren AYN, Sehested A, Viscardi E, Wormdal OM, Zapotocky M, Ziegler DS, Koch A, Hernáiz Driever P, Witt O, Capper D, Sahm F, Jones DTW, van Tilburg CM. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. *Neuro Oncol.* (2023); 25(11), 2087–2097. doi:10.1093/neuonc/noad078.
- 38 Hebert R, Cullinan N, Armstrong L, Blood KA, Brossard J, Brunga L, Cacciotti C, Caswell K, Cellot S, Coltin H, Deyell RJ, Felton K, Fernandez CV, Fleming AJ, Gibson P, Hammad R, Jabado N, Johnston DL, Lafay-Cousin L, Larouche V, Leblanc-Desrochers C, Michaeli O, Perrier R, Pike M, Say J, Schiller I, Toupin AK, Vairy S, van Engelen K, **Waespe N**, Villani A, Foulkes WD, Malkin D, Reichman L, Goudie C. Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes. *J Med Genet.* (2023); 60(12), 1218–1223. doi:10.1136/jmg-2023-109376.
- 39 Heesen P, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, Eich H, Ek T, Gelderblom H, Harges J, Haveman L, Jabar S, Hartmann W, Andreou D, Hauser P, Kersting J, Juergens H, Kanerva J, **Kühne T**, Raciborska A, Rascon J, Streitbürger A, Timmermann B, Uhlenbruch Y, Dirksen U. Association between local treatment modalities and event-free survival, overall survival, and local recurrence in patients with localised Ewing Sarcoma. Report from the Ewing 2008 trial. *Eur J Cancer.* (2023); 192, 113260. doi:10.1016/j.ejca.2023.113260.
- 40 Heilmann J, Vieth S, Möricke A, Attarbaschi A, Barbaric D, **Bodmer N**, Colombini A, Dalla-Pozza L, Elitzur S, Izraeli S, Mann G, Niggli F, Silvestri D, Stary J, Rizzari C, Valsecchi MG, Zapotocka E, Zimmermann M, Cario G, Schrappe M, Conter V. Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia. *Haematologica.* (2023); 108(12), 3278–3286. doi:10.3324/haematol.2022.281788.
- 41 Heipertz AE, Pajtlér KW, Pfaff E, Schramm K, Blattner-Johnson M, Milde T, Jones BC, Zuliani C, Hutter C, Lohi O, Kattamis A, Dachowska-Kalwak I, Nilsson A, **Gerber NU**, Langenberg KPS, Goemans B, Zwaan CM, Molenaar JJ, Jäger N, Dirksen U, Witt R, Pfister SM, Jones DTW, Kopp-Schneider A, Witt O, van Tilburg CM. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. *JCO Precis Oncol.* (2023); 7, e2300015. doi:10.1200/PO.23.00015. Erratum in: *JCO Precis Oncol.* (2023); 7, e2300341.
- 42 Huang Y, Drakul A, Sidhu J, Rauwolf KK, Kim J, Bornhauser BC, **Bourquin JP**. MSC.sensor: Capturing cancer cell interactions with stroma for functional profiling. *SLAS Discov.* (Epub 2023); S2472-5552(23)00061-8. doi:10.1016/j.slasd.2023.08.003.
- 43 Ilic A, Sievers Y, Roser K, **Scheinemann K**, Michel G. The information needs of relatives of childhood cancer patients and survivors: A systematic review of qualitative evidence. *Patient Educ Couns.* (2023); 114, 107840. doi:10.1016/j.pec.2023.107840.
- 44 Imbach P, **Schifferli A**, **Kühne T**. Introduction to the special issue: Refractory ITP. *Br J Haematol.* (2023); 203(1), 7–9. doi:10.1111/bjh.19080.
- 45 Jauch AJ, Bignucolo O, Seki S, Ghraichy M, Delmonte OM, von Niederhäusern V, Higgins R, Ghosh A, Nishizawa M, Tanaka M, Baldrich A, Köppen J, Hirsiger JR, Hupfer R, Ehl S, Rensing-Ehl A, Hopfer H, Prince SS, Daley SR, Marquardsen FA, Meyer BJ, Tamm M, Daikeler TD, **Diesch T**, **Kühne T**, Helbling A, Berkemeier C, Heijnen I, Navarini AA, Trück J, de Villartay JP, Oxenius A, Berger CT, Hess C, Notarangelo LD, Yamamoto H, Recher M. Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency. *J Allergy Clin Immunol.* (2023); 152(2), 500–516. doi:10.1016/j.jaci.2023.03.022.
- 46 Joye R, Wacker J, Nguyen DA, Hachulla AL, Maggio ABR, **Cimasoni L**, Lador F, **Ansari M**, Beghetti M. Dual-energy computed tomography to detect early pulmonary vascular changes in children with sickle cell disease: a pilot study. *Front Pediatr.* (2023); 11, 1221977. doi:10.3389/fped.2023.1221977.
- 47 Jung R, Zürcher SJ, **Schindera C**, Braun J, Deng WH, **von der Weid NX**, Rueegg CS, Kriemler S. Adherence and contamination in a 1-year physical activity program in childhood cancer survivors: A report from the SURfit study. *Cancer Med.* (2023); 12(13), 14731–14741. doi:10.1002/cam4.6096.
- 48 Jung R, Zürcher SJ, **Schindera C**, Eser P, Meier C, Schai A, Braun J, Deng WH, Hebestreit H, Neuhaus C, Schaeff J, Rueegg CS, **von der Weid NX**, Kriemler S. Effect of a physical activity intervention on lower body bone health in childhood cancer survivors: A randomized controlled trial (SURfit). *Int J Cancer.* (2023); 152(2), 162–171. doi:10.1002/ijc.34234.
- 49 **Kasteler R**, Fuchs P, **Oth M**, **Scheinemann K**. Interventions to improve neurocognitive late-effects in pediatric and adolescent CNS tumor patients and survivors – a systematic review. *Front Oncol.* (2023); 13, 1150166. doi:10.3389/fonc.2023.1150166.
- 50 **Kasteler R**, **Oth M**, Halbeisen FS, Mader L, Singer F, Rössler J, **von der Weid NX**, **Ansari M**, Kuehni CE. Longitudinal assessment of lung function in Swiss childhood cancer survivors – A multicenter cohort study. *Pediatr Pulmonol.* (Epub 2023); 59(1), 169–180. doi:10.1002/ppul.26738.
- 51 Kersting J, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, Eich H, Ek T, Gelderblom H, Harges J, Haveman L, Hartmann W, Hauser P, Heesen P, Juergens H, Kanerva J, **Kühne T**, Raciborska A, Rascon J, Rechl V, Streitbürger A, Timmermann B, Uhlenbruch Y, Dirksen U. Effect of Radiotherapy Dose on Outcome in Nonmetastatic Ewing Sarcoma. *Adv Radiat Oncol.* (2023); 8(4), 101269. doi:10.1016/j.adro.2023.101269.

Publications cited in PubMed or in peer reviewed journals

- 52 Killburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, Driever PH, Bailey S, Perreault S, McCowage G, Waanders AJ, Ziegler DS, Witt O, Baxter PA, Kang HJ, Hassall TE, Han JW, Hargrave D, Franson AT, Yalon Oren M, Toledano H, Larouche V, Kline C, Abdelbaki MS, Jabado N, Gottardo NG, **Gerber NU**, Whipple NS, Segal D, Chi SN, Oren L, Tan EEK, Mueller S, Cornelio I, McLeod L, Zhao X, Walter A, Da Costa D, Manley P, Blackman SC, Packer RJ, Nysom K. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. *Nat Med.* (Epub 2023); 30(1), 207–217. doi:10.1038/s41591-023-02668-y.
- 53 Koch R, Haveman L, Ladenstein R, Brichard B, Jürgens H, Cyprova S, van den Berg H, Hassenpflug W, Raciborska A, Ek T, Baumhoer D, Egerer G, Kager L, Renard M, Hauser P, Burdach S, Bovee JVMG, Hong AM, Reichardt P, Kruseova J, Streibbürger A, **Kühne T**, Kessler T, Bernkopf M, Butterfaß-Bahloul T, Dhooge C, Bauer S, Kiss J, Paulussen M, Bonar F, Ranft A, Timmermann B, Rascon J, Vieth V, Kanerva J, Faldum A, Hartmann W, Hjorth L, Bhadri VA, Metzler M, Gelderblom H, Dirksen U. Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial. *Clin Cancer Res.* (2023); 29(24), 5057-5068. doi:10.1158/1078-0432.CCR-23-1966.
- 54 **Koenig C**, Lehrnbecher T. Diagnostics and therapy of paediatric patients with febrile neutropenia. *EJC Paediatric Oncology.* (2023); 2, 100116. doi:10.1016/j.ejcped.2023.100116.
- 55 Kugler E, Madiwale S, Yong D, Thoms JAI, Birger Y, Sykes DB, Schmoeller J, Drakul A, Priebe V, Yassin M, Aqaq N, Rein A, Fishman H, Geron I, Chen CW, Raught B, Liu Q, Ogana H, Liedke E, **Bourquin JP**, Zuber J, Milyavsky M, Pimanda J, Privé GG, Izraeli S. The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG. *Nat Commun.* (2023); 14(1), 5871. doi:10.1038/s41467-023-41067-2.
- 56 Labarque V, Mancuso ME, **Kartal-Kaess M**, Ljung R, Mikkelsen TS, Andersson NG. F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project. *Res Pract Thromb Haemost.* (2023); 7(1):100036. doi:10.1016/j.rpth.2023.100036.
- 57 Lacerda A, Martínez MA, Dumont B, Leiss U, Kokkinou G, **Scheinemann K**, Craig F. Embracing paediatric palliative care in paediatric oncology from diagnosis onwards. *Pediatr Blood Cancer.* (2023); 70(10), e30561. doi:10.1002/pbc.30561.
- 58 Larrue C, Mouche S, Lin S, Simonetta F, **Scheidegger NK**, Poulain L, Birsén R, Sarry JE, Stegmaier K, Tamburini J. Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. *Leukemia.* (2023); 37(4), 765–775. doi:10.1038/s41375-023-01835-x.
- 59 Lehrnbecher T, Robinson PD, Ammann RA, Fisher B, Patel P, Phillips R, Beauchemin MP, Carlesse F, Castagnola E, Davis BL, Elgarten CW, Groll AH, Haeusler GM, **Koenig C**, Santolaya ME, Tissing WJE, Wolf J, Alexander S, Hu H, Dupuis LL, Sung L. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update. *J Clin Oncol.* (2023); 41(9), 1774–1785. doi:10.1200/JCO.22.02224.
- 60 Ligon JA, Ramakrishna S, **Ceppi F**, Calkoen FGJ, Diorio C, Davis KL, Jacoby E, Gottschalk S, Schultz LM, Capitini CM. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities. *Transplant Cell Ther.* (Epub 2023); S2666-6367(23)01615-9. doi:10.1016/j.jtct.2023.10.012.
- 61 Lilly JV, Rokita JL, Mason JL, Patton T, Stefankiewicz S, Higgins D, Trooskin G, Larouci CA, Arya K, Appert E, Heath AP, Zhu Y, Brown MA, Zhang B, Farrow BK, Robins S, Morgan AM, Nguyen TQ, Frenkel E, Lehmann K, Drake E, Sullivan C, Plisiewicz A, Coleman N, Patterson L, Koptyra M, Helili Z, Van Kuren N, Young N, Kim MC, Friedman C, Lubneuski A, Blackden C, Williams M, Baubet V, Tauhid L, Galanaugh J, Boucher K, Ijaz H, Cole KA, Choudhari N, Santi M, Moulder RW, Waller J, Rife W, Diskin SJ, Mateos M, Parsons DW, Pollack IF, Goldman S, Leary S, Caporalini C, Buccoliero AM, Scagnetti M, Hausler D, Hanson D, Firestein R, Cain J, Phillips JJ, Gupta N, Mueller S, Grant G, Monje-Deisseroth M, Partap S, Greenfield JP, Hashizume R, Smith A, Zhu S, Johnston JM, Fangusaro JR, Miller M, Wood MD, Gardner S, Carter CL, Prolo LM, Pisapia J, Pehlivan K, Franson A, Niaz T, Rubin J, Abdelbaki M, Ziegler DS, Lindsay HB, **Guerreiro Stucklin AS**, **Gerber NU**, Vaske OM, Quinsey C, Rood BR, Nazarian J, Raabe E, Jackson EM, Stapleton S, Lober RM, Kram DE, Koschmann C, Storm PB, Lulla RR, Prados M, Resnick AC, Waanders AJ. The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. *Neoplasia.* (2023); 35, 100846. doi:10.1016/j.neo.2022.100846.
- 62 Matzdorff A, Alesci SR, Gebhart J, Holzhauser S, Hütter-Krönke ML, **Kühne T**, Meyer O, Ostermann H, Pabinger I, Rummel M, Sachs UJ, Stauch T, Trautmann-Grill K, Wörmann B. Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment - Recommendations from an Expert Group from Austria, Germany, and Switzerland. *Oncol Res Treat.* (2023); 46 Suppl 2:5-44. doi:10.1159/000529662.
- 63 Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, **Ceppi F**, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hrásková A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. *Lancet Oncol.* (2023); 24(3), 252–261. doi:10.1016/S1470-2045(23)00019-0.
- 64 Meier CM, Fuchs J, von Schweinitz D, Stein R, Wagenpfeil S, Kager L, Schenk JP, Vokuhl C, Melchior P, Welter N, **Furtwängler R**, Graf N. Surgical Factors Influencing Local Relapse and Outcome in the Treatment of Unilateral Nephroblastoma. *Ann Surg.* (2023); 278(2), e360-e367. doi:10.1097/SLA.0000000000005690.
- 65 Meier CM, **Furtwängler R**, Mergen M, Welter N, Melchior P, Schenk JP, Vokuhl C, Kager L, **Kroiss S**, Wagenpfeil S, Graf N. Impact of Time to Surgery on Outcome in Wilms Tumor Treated with Preoperative Chemotherapy. *Cancers (Basel).* (2023); 15(5), 1494. doi:10.3390/cancers15051494.
- 66 Mejribi M, **Renella R**, Candotti F, Jaques C, Holzinger D, Hofer M, Theodoropoulou K. PSTPIP1-Associated Myeloid-Related Proteinemia Inflammatory (PAMI) Syndrome: A Systematic Review. *Genes (Basel).* (2023); 14(8), 1655. doi:10.3390/genes14081655.
- 67 Michel G, Raguindin PF, Priboi C, Ilic A, Holmer P, **Scheinemann K**, GROKKids Project. Acute and long-term psychosocial consequences in grandparents when a grandchild is diagnosed with cancer - the GROKKids Project: a population-based mixed-methods study protocol. *BMC Psychol.* (2023); 11(1), 280. doi:10.1186/s40359-023-01309-w.

Publications cited in PubMed or in peer reviewed journals

- 68 Moreno L, Teira P, Croop JM, **Gerber NU**, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. *Front Pediatr.* (2023); 11, 1183295. doi:10.3389/fped.2023.1183295.
- 69 Möricke A, Rizzari C, Alten J, Attarbaschi A, Beier R, Biondi A, Burkhardt B, **Bodmer N**, Boos J, Cario G, Conter V, Flotho C, Kulozik A, Lanvers-Kaminsky C, Mann G, Niggli F, Silvestri D, von Stackelberg A, Stanulla M, Valsecchi MG, Schrappe M, Zimmermann M. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction. *Hemisphere.* (2023); 7(6), e888. doi:10.1097/H59.0000000000000888.
- 70 Mynarek M, Obrecht D, Sill M, Sturm D, Kloth-Stachnau K, Selt F, Ecker J, von Hoff K, Juhnke BO, Goschzik T, Pietsch T, Bockmayr M, Kool M, von Deimling A, Witt O, Schüller U, Benesch M, **Gerber NU**, Sahn F, Jones DTW, Korshunov A, Pfister SM, Rutkowski S, Milde T. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. *Acta Neuropathol.* (2023); 145(1), 97–112. doi:10.1007/s00401-022-02522-4.
- 71 Nemes K, Benesch M, Kolarova J, Johann P, Hasselblatt M, Thomas C, Bens S, Glaser S, Ammerpohl O, Liaugaudiene O, Sadeghpour A, **von der Weid NX**, Schmid I, Gidding C, Erdreich-Epstein A, Khurana C, Ebetsberger-Dachs G, Lemmer A, Khatib Z, Hernández Marqués C, Pears J, Quehenberger F, Kordes U, Vokuhl C, Gerss J, Schwarz H, Bison B, Biegel JA, Siebert R, Frühwald MC. Rhabdoid tumors in patients conceived following ART: is there an association? *Hum Reprod.* (2023); 38(10), 2028–2038. doi:10.1093/humrep/dead154.
- 72 Ng CH, Obrecht D, Wells O, Zapotocky M, Sumerauer D, Coltin H, Khuong-Quang DA, Eisenstat DD, Kinross KM, White CL, Algar EM, Luck A, Witt H, Schüller U, Mynarek M, Pietsch T, **Gerber NU**, Benesch M, Warmuth-Metz M, Kortmann R, Bison B, Taylor MD, Rutkowski S, Pfister SM, Jones DT, Gottardo NG, von Hoff K, Pajtler KW, Ramaswamy V, Hansford JR. A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma. *Neurooncol Adv.* (2023); 5(1), vdad057. doi:10.1093/nojnl/vdad057.
- 73 Ortiz MV, **Koenig C**, Armstrong AE, Brok J, de Camargo B, Mavinkurve-Groothuis AMC, Herrera TBV, Venkatramani R, Woods AD, Dome JS, Spreafico F. Advances in the clinical management of high-risk Wilms tumors. *Pediatr Blood Cancer.* (2023); 70, Suppl 2:e30342. doi:10.1002/pbc.30342.
- 74 Passweg JR, Baldomero H, **Ansari M**, Arber C, Chalandon Y, Daskalakis M, **Diepold M**, **Diesch T**, Duchosal MA, Gerull S, **Güngör T**, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter JP; Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. *Hematol Oncol.* (Epub 2023). doi:10.1002/hon.3241.
- 75 Paun L, Lavé A, Jannelli G, Egervari K, Janssen I, Schaller K, **von Bueren AO**, Bartoli A. Pediatric Posterior Fossa ATRT: A Case Report, New Treatment Strategies and Perspectives. *Brain Sci.* (2023); 13(5), 712. doi:10.3390/brainsci13050712.
- 76 Perwein T, Giese B, Nussbaumer G, **von Bueren AO**, van Buien M, Benesch M, Kramm CM. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study. *J Neurooncol.* (2023); 161(3), 525–538. doi:10.1007/s11060-023-04241-6.
- 77 Politis G, Wagenpfeil S, Welter N, Mergen M, **Furtwängler R**, Graf N. An Observational Case-Control Study on Parental Age and Childhood Renal Tumors. *Cancers (Basel).* (2023); 15(21), 5144. doi:10.3390/cancers15215144.
- 78 Pomella S, Danielli SG, Alaggio R, **Breunis WB**, Hamed E, Selve J, Wachtel M, Walters ZS, Schäfer BW, Rota R, Shipley JM, Hettmer S. Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma. *Cancers (Basel).* (2023); 15(10):2823. doi:10.3390/cancers15102823.
- 79 Radauer-Plank AC, **Diesch T**, Schneider M, Sommerhäuser G, Friedrich LA, Salow V, Dülberg J, **Diepold M**, Rovó A, Njue LM, Drexler B, Infanti L, **Kroiss S**, Merki R, **Scheinemann K**, Eisenreich B, Hegemann I, Mandic L, Kager L, Borgmann-Staudt A, Schilling R, Roll S, Balcerak M. Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies. *Pediatr Blood Cancer.* (2023); 70(7), e30359. doi:10.1002/pbc.30359.
- 80 Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, De Moerloose B, Schmiegelow K, Burns MA, Elitzur S, Pieters R, Attarbaschi A, Yeoh A, Pui CH, Stary J, Cario G, **Bodmer N**, Moorman AV, Buldini B, Vora A, Valsecchi MG. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. *J Clin Oncol.* (2023); 41(32), 5025–5034. doi:10.1200/JCO.23.00088.
- 81 Ranta S, Motwani J, Blatny J, Bühlren M, Carcao M, Chambost H, Escuriola C, Fischer K, **Kartal-Kaess M**, de Kovel M, Kenet G, Male C, Nolan B, d'Oiron R, Olivier M, Zapotocka E, Andersson NG, Königs C. Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres. *Haemophilia.* (2023); 29(5), 1291–1298. doi:10.1111/hae.14847.
- 82 Rensing-Ehl A, Lorenz MR, Führer M, Willenbacher W, Willenbacher E, Sopper S, Abinun M, Maccari ME, König C, Haegeler P, Fuchs S, Castro C, Kury P, Pelle O, Klemann C, Heeg M, Thalhammer J, Wegehaupt O, Fischer M, Goldacker S, Schulte B, Biskup S, Chatelain P, Schuster V, Warnatz K, Grimbacher B, Meinhardt A, Holzinger D, Oommen PT, Hinze T, Hebart H, Seeger K, Lehmborg K, Leahy TR, Claviez A, Vieth S, **Schilling FH**, Fuchs I, Groß M, Rieux-Laucat F, Magerus A, Speckmann C, Schwarz K, Ehl S; ALPS Study Group. Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing. *J Allergy Clin Immunol.* (Epub 2023); 153(1), v297-308.e12. doi:10.1016/j.jaci.2023.11.006.
- 83 Reulen RC, Winter DL, Diallo I, Veres C, Llanas D, Allodji RS, Bagnasco F, Bárdi E, Feijen EAM, Alessi D, Fidler-Benaoudia MM, Høgholt S, Teepen JC, Linge H, Haddy N, Byrne J, Debiche G, Grabow D, Gudmundsdottir T, Fauchery R, Zrafi W, Michel G, Øfstaas H, Kaatsch P, Vu-Bezin G, Jenkinson H, Kaiser M, Skinner R, Cole T, **Waespe N**, Sommer G, Nordenfelt S, Jankovic M, Lähteenmäki Taalas T, Maule MM, van der Pal HJH, Ronckers CM, van Leeuwen FE, Kok JL, Terenzi M, Winther Gunnes M, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki PM, Zdravec Zalete L, Kuehni CE, Winther JF, Kremer LCM, Hjorth L, de Vathaire F, Hawkins MM. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study. *J Clin Oncol.* (2023); 41(21), 3735–3746. doi:10.1200/JCO.22.02045. Erratum in: *J Clin Oncol.* (2024); 42(2), 245.



Publications cited in PubMed or in peer reviewed journals

- 84 Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, Bufalo FD, Rives S, Jacoby E, Balduzzi A, **Bourquin JP**, Baruchel A. Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed. *J Clin Oncol.* (Epub 2023); 42(3), 253–257. doi:10.1200/JCO.23.01314.
- 85 Rowland L, Smart B, Brown A, Dettorre GM, Gocho Y, Hunt J, Yang W, Yoshimura S, Reyes N, Du G, John A, Maxwell D, Stock W, Kornblau S, Relling MV, Inaba H, Pui CH, **Bourquin JP**, Karol SE, Mullighan CG, Evans WE, Yang JJ, Crews KR. Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. *Bio Protoc.* (2023); 13(15), e4731. doi:10.21769/BioProtoc.4731.
- 86 Rueegg CS, Zürcher SJ, **Schindera C**, Jung R, Deng WH, Banteli I, Schaeff J, Hebestreit H, **von der Weid NX**, Kriemler S. Effect of a 1-year physical activity intervention on cardiovascular health in long-term childhood cancer survivors—a randomised controlled trial (SURfit). *Br J Cancer.* (2023); 129(8), 1284–1297. doi:10.1038/s41416-023-02410-y.
- 87 Sanalkumar R, Dong R, Lee L, Xing YH, Iyer S, Letovanec I, La Rosa S, Finzi G, Musolino E, Papat R, Chebib I, Nielsen GP, **Renella R**, Cote GM, Choy E, Aryee M, Stegmaier K, Stamenkovic I, Rivera MN, Riggi N. Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity. *Sci Adv.* (2023); 9(13), eabo3789. doi:10.1126/sciadv.abo3789.
- 88 Santschi M, Ammann RA, Agyeman PKA, **Ansari M**, **Bodmer N**, **Brack E**, **Koenig C**. Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study. *PLoS One.* (2023); 18(8), e0287233. doi:10.1371/journal.pone.0287233.
- 89 **Schifferli A**, Le Gavrian G, Aladjidi N, Moulis G, Godeau B, **Kühne T**. Chronic refractory immune thrombocytopenia in adolescents and young adults. *Br J Haematol.* (2023); 203(1), 36–42. doi:10.1111/bjh.19081.
- 90 **Schifferli A**, Moulis G, Godeau B, Leblanc T, Aladjidi N, Michel M, Leverger G, Elalfy M, Grainger J, Chitlur M, Heiri A, Holzhauser S, Le Gavrian G, Imbach P, **Kühne T**. Adolescents and young adults with newly diagnosed primary immune thrombocytopenia. *Haematologica.* (2023); 108(10), 2783–2793. doi:10.3324/haematol.2022.282524.
- 91 **Schifferli A**, Rüfer A, Rovo A, Nimmerjahn F, Cantoni N, Holbro A, Favre G, Dirks J, Wieland A, Faeth H, Pereira R, **Kühne T**. Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. *Br J Haematol.* (2023); 203(1), 119–130. doi:10.1111/bjh.19074.
- 92 Schladerer SP, **Ott M**, **Scheinemann K**. Quality criteria for pediatric oncology centers: A systematic literature review. *Cancer Med.* (2023); 12(18), 18999–19012. doi:10.1002/cam4.6452.
- 93 Schmutz M, Franzoso FD, Winkler J, **Kroiss S**, Seiler M, Speer O, Rand ML. IVIg treatment increases thrombin activation of platelets and thrombin generation in paediatric patients with immune thrombocytopenia. *Br J Haematol.* (2023); 201(6), 1209–1219. doi:10.1111/bjh.18702.
- 94 Seydoux C, Uppugunduri CRS, Medinger M, Nava T, Halter J, Heim D, Chalandon Y, Schanz U, Nair G, Cantoni N, Passweg JR, **Ansari M**. Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan. *Bone Marrow Transplant.* (2023); 58(7), 811–816. doi:10.1038/s41409-023-01963-z. Erratum in: *Bone Marrow Transplant.* (2023).
- 95 Sláma T, Belle FN, Strebel S, Christen S, Hägler-Laube E, Roessler J, Kuehni CE, **von der Weid NX**, **Schindera C**. Prevalence and factors associated with cancer-related fatigue in Swiss adult survivors of childhood cancer. *J Cancer Surviv.* (Epub 2023). doi:10.1007/s11764-023-01413-1.
- 96 Stanulla M, Schewe DM, Bornhauser BC, **Bourquin JP**, Eckert C, Eberl W, Wolf S, Wolf J, Vogiatzi F, Bergmann AK, Cario G, Beier R, Sauer M, Kratz CP, Maecker-Kolhoff B. Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia. *Ann Hematol.* (2023); 102(3), 669–672. doi:10.1007/s00277-023-05083-y.
- 97 Strebel S, Mader L, Jörger P, **Waespe N**, Uhlmann S, von der Weid N, **Ansari M**, Kuehni C. Hearing loss after exposure to vincristine and platinum-based chemotherapy among childhood cancer survivors. *EJC.* (2023). doi:10.1016/j.ejcped.2023.100017
- 98 Sturm D, Capper D, Andreiuolo F, Gessi M, Kölsche C, Reinhardt A, Sievers P, Wefers AK, Ebrahimi A, Suwala AK, Gielen GH, Sill M, Schrimpf D, Stichel D, Hovestadt V, Daenekas B, Rode A, Hamelmann S, Previti C, Jäger N, Buchhalter I, Blattner-Johnson M, Jones BC, Warmuth-Metz M, Bison B, Grund K, Sutter C, Hirsch S, Dikow N, Hasselblatt M, Schüller U, Koch A, **Gerber NU**, White CL, Buntine MK, Kinross K, Algar EM, Hansford JR, Gottardo NG, Schuhmann MU, Thomale UW, Hernáiz Driever P, Gnekow A, Witt O, Müller HL, Calaminus G, Fleischhack G, Kordes U, Mynarek M, Rutkowski S, Frühwald MC, Kramm CM, von Deimling A, Pietsch T, Sahn F, Pfister SM, Jones DTW. Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. *Nat Med.* (2023); 29(4), 917–926. doi:10.1038/s41591-023-02255-1. Erratum in: *Nat Med.* (2024); 30(1), 306.
- 99 Sturm D, Capper D, Andreiuolo F, Gessi M, Kölsche C, Reinhardt A, Sievers P, Wefers AK, Ebrahimi A, Suwala AK, Gielen GH, Sill M, Schrimpf D, Stichel D, Hovestadt V, Daenekas B, Rode A, Hamelmann S, Previti C, Jäger N, Buchhalter I, Blattner-Johnson M, Jones BC, Warmuth-Metz M, Bison B, Grund K, Sutter C, Hirsch S, Dikow N, Hasselblatt M, Schüller U, Koch A, **Gerber NU**, White CL, Buntine MK, Kinross K, Algar EM, Hansford JR, Gottardo NG, Schuhmann MU, Thomale UW, Hernáiz Driever P, Gnekow A, Witt O, Müller HL, Calaminus G, Fleischhack G, Kordes U, Mynarek M, Rutkowski S, Frühwald MC, Kramm CM, von Deimling A, Pietsch T, Sahn F, Pfister SM, Jones DTW. Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. *Nat Med.* (2024); 30(1):306. doi:10.1038/s41591-023-02652-6. Erratum for: *Nat Med.* (2023); 29(4), 917–926.
- 100 Tonn S, Korshunov A, Obrecht D, Sill M, Spohn M, von Hoff K, Milde T, Pietsch T, Goschzik T, Bison B, Juhnke BO, Struve N, Sturm D, Sahn F, Bockmayr M, Friedrich C, **von Bueren AO**, **Gerber NU**, Benesch M, Jones DTW, Kool M, Wefers AK, Schüller U, Pfister SM, Rutkowski S, Mynarek M. Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups. *Neuro Oncol.* (2023); 25(8):1518–1529. doi:10.1093/neuonc/noad027.

Publications cited in PubMed or in peer reviewed journals


- 101 Tramsen L, Bochennek K, Sparber-Sauer M, Salzmann-Manrique E, Scheer M, **Dantonello T**, Borkhardt A, Dirksen U, Thorwarth A, **Greiner J**, Ebinger M, Weclawek-Tompol J, Ladenstein R, Ljungman G, Hallmen E, Lehrnbecher T, Koscielniak E, Klingebiel T. Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials. *Cancers (Basel)*. (2023); 15(7), 2050. doi:10.3390/cancers15072050.
- 102 Trobaugh-Lotrario AD, Maibach R, Aronson DC, Rangaswami A, Häberle B, O'Neill AF, Schmid I, **Ansari M**, Hishiki T, Ranganathan S, Alaggio R, de Krijger RR, Tanaka Y, Cho SJ, Vokuhl C, Maxwell R, Krailo M, Hiyama E, Czaderna P, Finegold M, Feusner JH, Malogolowkin MH, Meyers RL, Lopez-Terrada D. Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC). *Cancers (Basel)*. (2023); 15(2), 467. doi:10.3390/cancers15020467.
- 103 van Schaik RH, Manolopoulos VG, Daly AK, Niemi M, Zukic B, Patrinos GP, Primorac D, Swen JJ, Ingelman-Sundberg M, Morris T, Molden E, Müller D, Pavlovic S, Russmann S, **Ansari M**, Henricks LM, den Broek WV, Florindi F, Bozina N, Akin D, Christrup L, Llerena A, Sipeky C, Stankovic S. The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress. *Pharmacogenomics*. (2023); 24(5), 243–246. doi:10.2217/pgs-2023-0013.
- 104 Vujanić GM, Graf N, D'Hooghe E, Chowdhury T, Vokuhl C, Al-Saadi R, Pritchard-Jones K, Melchior P, **Furtwängler R**. Outcomes of patients with Wilms' tumour stage III due to positive resection margins only: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies. *Int J Cancer*. (2023); 152(8), 1640–1647. doi:10.1002/ijc.34371.
- 105 **Waespe N**, Makar SJ, Dupanloup I, Rezzugi MA, Bittencourt H, Krajcinovic M, Kuehni CE, Nava T, **Ansari M**. A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome. *PLoS One*. (2023); 18(4), e0281892. doi:10.1371/journal.pone.0281892.
- 106 Wang Y, Ronckers CM, van Leeuwen FE, Moskowitz CS, Leisenring W, Armstrong GT, de Vathaire F, Hudson MM, Kuehni CE, Arnold MA, Demoor-Goldschmidt C, Green DM, Henderson TO, Howell RM, Ehrhardt MJ, Neglia JP, Oeffinger KC, van der Pal HJH, Robison LL, Schaapveld M, Turcotte LM, **Waespe N**, Kremer LCM, Teepen JC; International Consortium for Pooled Studies on Subsequent Malignancies after Childhood and Adolescent Cancer. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. *Nat Med*. (2023); 29(9), 2268–2277. doi:10.1038/s41591-023-02514-1.
- 107 **Weiser A**, Hengartner H, Kottke R, Grethen P, Toelle SP, **Gerber NU**, Grotzer MA, **Guerreiro Stucklin AS**. Treatment of NF1-Associated Optic Pathway/Hypothalamic Gliomas in Patients With Diencephalic Syndrome. *J Pediatr Hematol Oncol*. (2023); 45(4), e543-e546. doi:10.1097/MPH.0000000000002569.
- 108 **Weiser A**, Sanchez Bergman A, Machaalani C, Bennett J, Roth P, Reimann RR, Nazarian J, **Guerreiro Stucklin AS**. Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults. *Front Oncol*. (2023); 13, 1254645. doi:10.3389/fonc.2023.1254645.
- 109 Zeckanovic A, Fuchs P, Heesen P, **Bodmer N**, **Ott M**, **Scheinemann K**. Pediatric-Inspired Regimens in the Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults: A Systematic Review. *Curr Oncol*. (2023); 30(9), 8612–8632. doi:10.3390/curroncol30090625.
- 110 Zimmermann K, Simon M, **Scheinemann K**, **Tinner EM**, Widler M, Keller S, Fink G, Mitterer S, Gerber AK, von Felten S, Bergstraesser E. Correction: Specialised Paediatric Palliative CaRe: Assessing family, healthcare professionals and health system outcomes in a multi-site context of various care settings: SPhAERA study protocol. *BMC Palliat Care*. (2023); 22(1), 13. doi:10.1186/s12904-023-01136-1. Erratum for: *BMC Palliat Care*. (2022); 21(1):188.

#### Publications in not peer reviewed journals or not cited in PubMed

- 1 **Diezi M.**, Fawer Caputo C, Naef F, Schooling of Students with Cancer and the Role of Teachers: an Exploratory Study in French-Speaking Switzerland. *Psycho-Oncol.* (2023); 17:65–70. doi:10.3166/psn-2022-0234.
- 2 Lengnick K, **Vetter C**, Klein A, Meier O. Opsoklonus-Myoklonus-Ataxie-Syndrom (OMAS) mit initialer Präsentation einer postinfektiösen cerebellären Ataxie – eine diagnostische Herausforderung. *Neuropädiatrie in Klinik und Praxis.* (2023); 22.
- 3 **Oth M**, Nagy V, Stoll S, **Scheinemann K**. Cancer Survivorship. *Schweizerische Ärztezeitung.* (2023); 104(26):70-71.
- 4 **Schindera C**, Kuehni CE, **Tinner EM**. Long-term Survivorship bei pädiatrischen Tumoren. *info@onco-suisse* (2023); 13(7), 10–12.
- 5 Schneeberger A, **Scheinemann K**. Die spezialisierte Pädiatrische Palliative Care in der Schweiz aus Sicht der Kinderspitem. *Palliative ch.* (2023); 2, 39–44.

#### Book Chapters and others

- 1 **Furtwängler R**, Seitz G, Stein R. Tumoren der Blase und Prostata. In: Die Kinder- und Jugendurologie. Springer (2023); 501-512. doi:10.1007/978-3-662-63275-8\_40.



Give children  
with cancer a **future.**

Your will counts

Request our **guide**  
to making a will.

Find out more about current inheritance law,  
how you can draw up a will and the ways in which  
you can make SPOG a beneficiary in your will.

